Human IgG3 with extended half-life does not improve Fc-gamma receptor-mediated cancer antibody therapies in mice

Rens Braster; Simran Grewal; Remco Visser; Helga K. Einarsdottir; Marjolein van Egmond; Gestur Vidarsson; Marijn Bögels

doi:10.1371/journal.pone.0177736

Loading metrics

Open Access

Peer-reviewed

Research Article

Human IgG3 with extended half-life does not improve Fc-gamma receptor-mediated cancer antibody therapies in mice

Rens Braster,

Affiliation Department of Molecular Cell Biology and Immunology, VU University Medical Centre, Amsterdam, The Netherlands

http://orcid.org/0000-0002-4009-7877

⨯
Simran Grewal,

Affiliations Department of Molecular Cell Biology and Immunology, VU University Medical Centre, Amsterdam, The Netherlands, Department of Surgery, VU University Medical Centre, Amsterdam, The Netherlands
⨯
Remco Visser,

Affiliation Department of Experimental Immunohematology, Sanquin Research, and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
⨯
Helga K. Einarsdottir,

Affiliation Department of Experimental Immunohematology, Sanquin Research, and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
⨯
Marjolein van Egmond,

Affiliations Department of Molecular Cell Biology and Immunology, VU University Medical Centre, Amsterdam, The Netherlands, Department of Surgery, VU University Medical Centre, Amsterdam, The Netherlands
⨯
Gestur Vidarsson ,

Contributed equally to this work with: Gestur Vidarsson, Marijn Bögels

* E-mail: g.vidarsson@sanquin.nl

Affiliation Department of Experimental Immunohematology, Sanquin Research, and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
⨯
Marijn Bögels

Contributed equally to this work with: Gestur Vidarsson, Marijn Bögels

Affiliations Department of Molecular Cell Biology and Immunology, VU University Medical Centre, Amsterdam, The Netherlands, Department of Surgery, VU University Medical Centre, Amsterdam, The Netherlands
⨯

Human IgG3 with extended half-life does not improve Fc-gamma receptor-mediated cancer antibody therapies in mice

Rens Braster,
Simran Grewal,
Remco Visser,
Helga K. Einarsdottir,
Marjolein van Egmond,
Gestur Vidarsson,
Marijn Bögels

Published: May 19, 2017
https://doi.org/10.1371/journal.pone.0177736

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Cancers and neoplasms
Is the Subject Area "Cancers and neoplasms" applicable to this article?

Thanks for your feedback.
Macrophages
Is the Subject Area "Macrophages" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Lung and intrathoracic tumors
Is the Subject Area "Lung and intrathoracic tumors" applicable to this article?

Thanks for your feedback.
Colorectal cancer
Is the Subject Area "Colorectal cancer" applicable to this article?

Thanks for your feedback.
Head and neck cancers
Is the Subject Area "Head and neck cancers" applicable to this article?

Thanks for your feedback.
Antibody isotypes
Is the Subject Area "Antibody isotypes" applicable to this article?

Thanks for your feedback.
Antibody therapy
Is the Subject Area "Antibody therapy" applicable to this article?

Thanks for your feedback.